Smith & Nephew (LON:SN) Rating Reiterated by Shore Capital

Share on StockTwits

Smith & Nephew (LON:SN)‘s stock had its “sell” rating reiterated by equities research analysts at Shore Capital in a report issued on Monday, ThisIsMoney.Co.Uk reports.

Other research analysts have also issued reports about the company. Deutsche Bank reissued a “hold” rating on shares of Smith & Nephew in a report on Friday, July 12th. UBS Group raised their price target on Smith & Nephew from GBX 1,730 ($22.61) to GBX 1,830 ($23.91) and gave the company a “neutral” rating in a report on Tuesday, August 6th. Finally, Berenberg Bank lowered their price target on Smith & Nephew to GBX 2,250 ($29.40) and set a “buy” rating on the stock in a report on Friday, October 4th. One research analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the company’s stock. Smith & Nephew has a consensus rating of “Hold” and a consensus price target of GBX 1,654.38 ($21.62).

Shares of SN opened at GBX 1,694 ($22.14) on Monday. The firm has a market capitalization of $14.53 billion and a price-to-earnings ratio of 21.25. The company has a debt-to-equity ratio of 44.00, a quick ratio of 0.96 and a current ratio of 2.00. Smith & Nephew has a one year low of GBX 1,242.50 ($16.24) and a one year high of GBX 1,998.40 ($26.11). The stock’s fifty day moving average is GBX 1,897.03 and its 200-day moving average is GBX 1,749.70.

In other news, insider Virginia Bottomley bought 201 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were purchased at an average cost of GBX 1,939 ($25.34) per share, with a total value of £3,897.39 ($5,092.63).

About Smith & Nephew

Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.

Read More: The limitations of an equal weight rating

Analyst Recommendations for Smith & Nephew (LON:SN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.